Submit Manuscript Now
Current issue Archive Authors Profile
Research Articles Issue 2 · 2020 · pp. 175–179 · Issue page

THE SEQUENTIAL TREATMENT FOR HELICOBACTER PYLORI ERADICATION AS A FIRST-LINE THERAPY IN TYPE 2 DIABETIC PATIENTS

AM
Amelia GENUNCHE-DUMITRESCU1
DA
Daniela BADEA2
CR
Cristian MARINAS3
SM
Smaranda MITRAN4
TI
Tiberiu-Stefanita TENEA-COJAN5
1 Clinical Hospital of Emergency Craiova, 1 st Medical Clinic, University of Medicine and Pharmacy Craiova, Romania
2 Clinical Hospital of Emergency Craiova, Department of Physiology, University of Medicine and Pharmacy Craiova, Romania
3 Clinical Hos pital of Emergen cy Craiova, Department of Anatomy, University of Medicine and Pharmacy
4 University of Medicine and Pharmacy Craiova, Romania, Department of Physiology
5 CFR Hospital, Surgery Department, University of Medicine and Pharma cy Craiova, Romania
DOI https://doi.org/10.38173/RST.2020.20.2.18:175-179
Received 13 September 2020
Revised 4 Octomber 2020
Accepted 18 October 2020
Available Online 15 November 2020
Abstract
HELICOBACTER PYLORI (HP) IS A GRAM NEGATIVE BACTERIUM FOUND IN THE STOMACH AND DETERMINED CHRONIC GASTRITIS, PEPTIC ULCERS AND GASTRIC CANCER. IN PATIENTS WITH DIABETUS MELLITUS THE FREQUENCY OF HELICOBACTER PYLORI INFECTION WAS HIGHER COMPARATIV WIT H NONDIABETI CS. HELICOBACTER PYLORI INFECTION MAY INCREASE THE LEVEL OF GLYCOSYLATED HEMOGLOBIN IN DIABETIC PATIENTS.THE LEVELS OF GLICEMIA WAS CONTROLLED BY INSULIN OR ORAL HYPOGLICEMIC AGENTS WHILE THE DRUGS USED FOR ERADICATION OF HP INFECTION ARE PROTON PUMP INHIB ITORS, BISMUTH COMPOUNDS, METRONIDAZOLE, CLARITHROMYCIN, AMOXICILIN AND TETRACYCLINE.
Keywords
HELICOBACTER PYLORI DIABETUS MELLITUS
Full Text
The body of this article is intentionally hidden on the public page. Please use the PDF reader or the PDF download for the complete text.
References
[1]
Stenström B, Mendis A, Marshall B (August 2008). "Helicobacter pyl ori – The latest in diagnosis and treatment". Australian Family Physician. 37 (8): 608–612.
[2]
Pounder, R. E. and D. Ng , “The prevalence of Helicobacter pylori infection in different countries”, Alimentary Pharmacology & Therapeutics, vol. 9, supplement 2, pp. 33–39, 1995.
[3]
Chen Y, Blaser M ., Association between Gastric Helicobacter pylori colonization and glycated hemoglobin levels. Journal of Infectious Disease, 2012; 205:1195–202.
[4]
Malfertheiner, Peter; Megraud, Francis; Colm A O’Morain, A therton, John; Ax on, Anthony T R, Bazzoli, Franco; Gensini, Gian Franco; Gisbert, Javier P; Graham, David Y; Rokkas,Theodore; M El-Omar, Emad; Kuipers, Ernst J; The European Helicobacter Study Group (EHSG) - Management of Helicobacter pylori infection the Maastricht IV/ Florence Consensus Report.
[5]
Vaira D, Zullo A, Vakil N, et al . “Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial”, Annals of Internal Medicine, 2007; 146:556e63.
[6]
Graham DY, Fischbac h L. “Helicobacter pylori treatment in the era of increasing antibiotic resistance” . Gut 2010;59: 1143e53.
[7]
de Luis DA, de la Calle H, Roy G, de Argila CM, Valdezate S, Canton R, et al. “Helicobacter pylori infection and insulin -dependent diabetes mellitus” , Diabetes Resear ch and Clinical Practice, 1998; 39:143–6.
[8]
Devrajani BR, Shah SZ, Soomro AA, Devrajani T., “Type 2 diabetes mellitus: A risk factor for Helicobacter pylori infection: A hospital based case -control study”, International Journal of Diabetes in Developing Countris, 2010; 30:22–6.
[9]
Bener A, Micallef R, Afifi M, Derbala M, Al -Mulla HM, Usmani MA, et al., “Association between Type 2 diabetes mellitus and Helicobacter pylori infection”, Turkish Journal of Gastroenterology, 2007; 18:225– 9.
[10]
Gulcelik NE, Kaya E, Demirbas B, Culha C, Koc G, Ozkaya M, et al ., “Helicobacter pylori prevalence in diabetic patients and its relationship with dyspepsia and autonomic neuropathy”, Journal of Endocrinological Investigation, 2005; 28:214–7.
[11]
Devrajani, B. R., Sh ah, S . Z. A., Soo mro, A. A. and Devrajani,T., “Type 2 diabetes mellitus: a risk factor for Helicobacter pylori infection: a hospital based case -control study”, International Journal of Diabetes in Developing Countries, vol. 30, no. 1, pp. 22–26, 2010.